Why isn’t the media upfront about the progress and expectancy of vaccine?

by stoneyMaloney92

Look I’m all for optimism. I think it’s good to look forward to something in a time of difficulty, but I also feel that it’s equally if not more important to be realistic about expectations.

Lately the media has been pushing the progress of a vaccine discovery and having doctors vetting that it will be ready by the end of summer, mid fall, or by the end of the year. Trump even promises one by the end of the year (grain of salt).

I just don’t see it. I don’t know every single hoop that a vaccine has to go through to become approved, but I know there’s a lot which is why it’s always taken years in the past for anything else to be cleared.

For some grand reason if there is one by the end of the year, I can’t help but to think that corners were cut which can be dangerous.

READ  If you care about U.S. election security, *STOP* what you're doing and watch this

Thoughts?

 

Respond #1:

I think the media is just trying to stay on top of announced and published research and political promises.

I personally want to see more people talk about the fact that vaccines for SARS-CoV viruses historically fail to deliver intended results and harm young recipients. I want to hear someone officially talk about how variations in bat-based coronaviruses make a single vaccine almost useless against future mutations. Also, vetting processes usually take a long time for good reason: It’s important to know what a vaccine will do to a person long-term. If a vaccine is created that does offer any protection in the short term, what are the long-term side effects?

Edit: “Vaccine formulations that have been developed against SARS-CoV not only fail to protect animal models of aged populations, but also result in immunopathology in younger populations, where SARS disease is enhanced in vaccinated groups that are subsequently challenged with SARS-CoV [118,119]. In addition, vaccines generate memory immune responses to specific pathogens, and no vaccine formulations have been developed that are effective against multiple CoVs. Due to the diversity of BatCoVs, it seems unlikely that current therapeutic strategies targeting specific SARS-CoV or MERS-CoV antigens will be efficacious against future coronaviruses that emerge into the human population. Vaccines formulated against the SARS-CoV epidemic antigens do not offer effective protection against SARS-like BatCoVs that are currently circulating in bat populations [15]. Rather, a modular vaccine platform that can be rapidly adjusted for newly emergent viral antigens in potentially pandemic CoVs may be able to provide emergency vaccine coverage against emergent viral strains.”

READ  In 2008, Foreign Investors Owned More Than Half of the U.S. Treasury Market, Now They Own About 35%

www.tandfonline.com/doi/full/10.1080/17460441.2019.1581171